Therapeutic Asset Ratings
155 results matching 1 filter
129,757 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nevadistinel
Parkinson Disease
Aptinyx
P2
CCC
(48)
Radotinib
Parkinson Disease
Il-Yang Pharm. Co., Ltd.
P2
CCC
(48)
SFX-01 (SULFORAPHANE STABILIZED WITH .ALPHA. CYCLODEXTRIN)
Parkinson Disease
Central South University
P2
CCC
(48)
Silymarin
Parkinson Disease
Tanta University
P2
CCC
(48)
Tocovid Suprabio
Parkinson Disease
National Neuroscience Institute
P2
CCC
(48)
Valiloxybate
Parkinson Disease
XWPharma
P2
CCC
(48)
XJN010
Parkinson Disease
Guangzhou Novaken Pharm Co., Ltd.
P2
CCC
(48)
FLUTICASONE
Parkinson Disease
University of Nebraska
P1
CCC
(48)
Sargramostim
Parkinson Disease
University of Nebraska
P1
CCC
(48)
NORADRENALINE TARTRATE IMPURITY C
Parkinson Disease
University Hospital, Lille
P1/2
CCC
(48)
BUTYRIN
Parkinson Disease
Prabesh Kanel
P1/2
CC
(46)
DPA-714
Parkinson Disease
University of Alabama at Birmingham
P1/2
CC
(46)
Rapamycin
Parkinson Disease
Royan Institute
P1/2
CC
(46)
Midodrine
Parkinson Disease
Vanderbilt University Medical Center
P1
CC
(45)
AZD-0328
Parkinson Disease
King's College London
P2
CC
(44)
Her-096
Parkinson Disease
Herantis Pharma Plc.
P1
CC
(44)
ub-312
Parkinson Disease
NYU Langone Health
P1
CC
(44)
Amdx-2011P
Parkinson Disease
Amydis Inc.
P1/2
CC
(44)
Hypoestoxide
Parkinson Disease
University of Ibadan
P1/2
CC
(44)
PE 2I
Parkinson Disease
Universitaire Ziekenhuizen KU Leuven
P1/2
CC
(44)
Allogeneic Dopaminergic Neural Precursor Cell
Parkinson Disease
Nuwacell Biotechnologies Co., Ltd.
P1
CC
(42)
Dipraglurant
Parkinson Disease
Addex Pharma S.A.
P2/3
CC
(42)
[18F]MC225
Parkinson Disease
University Medical Center Groningen
P1/2
CC
(41)
ly3884961
Parkinson Disease
Prevail Therapeutics
P1/2
CC
(41)
Vent-02
Parkinson Disease
Ventus Therapeutics U.S., Inc.
P1/2
CC
(41)
Showing 76 to 100 of 155 assets
Previous
Page 4 of 7
Next
